Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:20 AM
Ignite Modification Date:
2025-12-25 @ 12:20 AM
NCT ID:
NCT06818058
Eligibility Criteria:
Inclusion Criteria:
* male or female, who is at least 18 years of age or older at the screening visit
* patients with clinical diagnosis of metastatic colorectal carcinoma planned to be treated with cetuximab or panitumumab injections as part of the chemotherapy protocol
* patients who can understand and sign the Informed Consent Form, can communicate with investigator,can understand and comply with requierements of the protocol, and can apply the study gel by himself/herself or have giver who can apply the product
* patients with predicted life expectency of \> 3 months
* patients willing and able to comply with all of the time commitements and procedural requirements of the clinical trial protocol
Exclusion Criteria:
* patients with medical history of EGFR treatment in the past 2 years
* patients with any underlying physical ,psychological or medical condition that, in the opinion of the invstigator, would make it unlikely that the patient will comply with the protocol or complete the study protocol
* patients with any uncotrolled or serious disease, or any medical or surgical condition,that may put the subject at significant risk (according to the investigator's judgement) if he/she participates in the clinical trial
* patients with history of other skin disorders (eg.atopic dermatitis,psoriasis,recurrent skin infections), or a history of illness that, in the opinion of the investigator, would confound the results of the study
* patients with significant skin disease other than EGFRi-induced folliculits within the same body areas planned for study drug application
* patients with a beard that would interfere with administration of the study drug and assessement of study endpoints
* patients with active infection within the treatment area ot in other body areas that requieres initiation of systemic antibiotics
* patients with known or suspected allergies or sensitivities to any components of the study drugs
* female patients who are pregnant or lactating
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT06818058
Study Brief:
Protocol Section:
NCT06818058